Viridian Therapeutics, Inc. (NASDAQ: VRDN)
$20.8400
+0.6400 ( -0.24% ) 491.0K
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Market Data
Open
$20.8400
Previous close
$20.2000
Volume
491.0K
Market cap
$1.66B
Day range
$20.2000 - $22.0550
52 week range
$11.4000 - $27.2000
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 14 | Apr 16, 2024 |
| 4 | Insider transactions | 1 | Apr 01, 2024 |
| 10-k | Annual reports | 100 | Feb 27, 2024 |
| 8-k | 8K-related | 17 | Feb 27, 2024 |
| 4 | Insider transactions | 1 | Feb 14, 2024 |
| 3 | Insider transactions | 2 | Feb 14, 2024 |
| 4 | Insider transactions | 1 | Feb 07, 2024 |
| 4 | Insider transactions | 1 | Jan 24, 2024 |
| 8-k | 8K-related | 16 | Jan 19, 2024 |
| 3 | Insider transactions | 1 | Jan 12, 2024 |